Management and evaluation of extra-articular manifestations in spondyloarthritis

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 6, 2012, Pages 413-422

  Van Der Horst Bruinsma, Irene E ^a   Nurmohamed, Michael T ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing spondylitis; anterior uveitis; arthritis; cardiac manifestations; enthesitis; IBD; psoriasis; spondyloarthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; ETANERCEPT; ETORICOXIB; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; PSORALEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ANKYLOSING SPONDYLITIS; AORTA VALVE REGURGITATION; ARTHRITIS; ATHEROSCLEROSIS; ATRIOVENTRICULAR BLOCK; BLINDNESS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; ENTERITIS; ENTHESITIS; EXTRAARTICULAR MANIFESTATION; EYE REDNESS; GLAUCOMA; HEART BUNDLE BRANCH BLOCK; HUMAN; IRIDOCYCLITIS; KINESIOTHERAPY; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PERIPHERAL ARTHRITIS; PHYSIOTHERAPY; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPONDYLARTHRITIS; UVEITIS;

EID: 84878374844     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12458372     Document Type: Review

References (79)

1. Bakland G. Gran J.T. Nossent J.C. (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70: 1921–1925.
2. Baraliakos X. Davis J. Tsuji W. Braun J. (2005 a) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52: 1216–1223.
3. Baraliakos X. Listing J. Brandt J. Zink A. Alten R. Burmester G. et al. (2005 b) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7: R439–R444.
4. Barkham N. Keen H. Coates L. O'Connor P. Hensor E. Fraser A. et al. (2009) Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60: 946–954.
5. Barnabe C. Hanley D. (2009) Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 39: 116–122.
6. Bergfeldt L. (1997) HLA-B27-Associated cardiac disease. Ann Intern Med 127: 621–629.
7. Brandt J. Khariouzov A. Listing J. Haibel H. Sorensen H. Rudwaleit M. et al. (2004) Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 31: 531–538.
8. Braun J. Baraliakos X. Hermann K. van der Heijde D. Inman R. Deodhar A. et al. (2012) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled go-raise study. Ann Rheum Dis 71: 878–884.
9. Braun J. Baraliakos X. Listing J. Davis J. van der Heijde D. Haibel H. et al. (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57: 639–647.
10. Braun J. Baraliakos X. Listing J. Sieper J. (2005) Decreased Incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52: 2447–2451.
11. Braun J. Bollow M. Remlinger G. Eggens U. Rudwaleit M. Distler A. et al. (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41: 58–67.
12. Braun J. Landewe R. Hermann K. Han J. Yan S. Williamson P. et al. (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab – results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54: 1646–1652.
13. Braun J. van Den Berg R. Baraliakos X. Boehm H. Burgos-Vargas R. Collantes-Estevez E. et al. (2011 a) 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70: 896–904.
14. Braun J. van der Horst-Bruinsma I. Huang F. Burgos-Vargas R. Vlahos B. Koenig A. et al. (2011 b) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63: 1543–1551.
15. Bremander A. Petersson I. Bergman S. Englund M. (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 63: 550–556.
16. Brewerton D. Gibson D. Goddard D. Jones T. Moore R. Pease C. et al. (1987) The myocardium in ankylosing spondylitis. a clinical, echocardiographic, and histopathological study. Lancet 1: 995–998.
17. de Vries M. van der Horst-Bruinsma I. van Hoogstraten I. van Bodegraven A. Von Blomberg B. Ratnawati H. et al. (2010) PANCA, ASCA, and OMPC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol 37: 2340–2344.
18. Dougados M. Behier J. Jolchine I. Calin A. van der Heijde D. Olivieri I. et al. (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44: 180–185.
19. El Maghraoui A. (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22: 554–560.
20. El-Shabrawi Y. Hermann J. (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109: 2342–2346.
21. Foster C. Tufail F. Waheed N. Chu D. Miserocchi E. Baltatzis S. et al. (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121: 437–440.
22. Goodson N. Brookhart A. Symmons D. Silman A. Solomon D. (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68: 367–372.
23. Gossec L. Smolen J. Gaujoux-Viala C. Ash Z. Marzo-Ortega H. van der Heijde D. et al. (2012) European League against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71: 4–12.
24. Haibel H. Rudwaleit M. Listing J. Heldmann F. Wong R. Kupper H. et al. (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58: 1981–1991.
25. Haibel H. Rudwaleit M. Listing J. Sieper J. (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64: 296–298.
26. Han C. Robinson D. Hackett M. Paramore L. Fraeman K. Bala M. (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33: 2167–2172.
27. Hanauer S. Feagan B. Lichtenstein G. Mayer L. Schreiber S. Colombel J. et al. (2002) Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359: 1541–1549.
28. Heuft-Dorenbosch L. Spoorenberg A. van Tubergen A. Landewe R. van Ver Tempel H. Mielants H. et al. (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62: 127–132.
29. Inman R. Davis J. van der Heijde D. Dickman L. Sieper J. Kim S. et al. (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58: 3402–3412.
30. Kary S. Worm M. Audring H. Huscher D. Renelt M. Sorensen H. et al. (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65: 405–407.
31. Khan M. (2003) Clinical features of ankylosing spondylitis. In: Ed. Hochberg M. Silman A. Smolen J. Weinblatt M. Weisman M. (eds), Rheumatology, vol. 2. London: Mosby-Wolfe. pp.1161–1181.
32. Lambert R. Salonen D. Rahman P. Inman R. Wong R. Einstein S. et al. (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum 56: 4005–4014.
33. Lekpa F. Farrenq V. Canoui-Poitrine F. Paul M. Chevalier X. Bruckert R. et al. (2012) Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 79: 47–50.
34. Linder R. Hoffmann A. Brunner R. (2004) Prevalence of the spondyloarthritides in patients with uveitis. J Rheumatol 31: 2226–2229.
35. Linssen A. Rothova A. Valkenburg H. Dekker-Saeys A. Luyendijk L. Kijlstra A. et al. (1991) The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci 32: 2568–2578.
36. Maksymowych W. Mallon C. Morrow S. Shojania K. Olszynski W. Wong R. et al. (2009) Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index. Ann Rheum Dis 68: 948–953.
37. McGonagle D. Emery P. (2000) Enthesitis, osteitis, microbes, biomechanics, and immune reactivity in ankylosing spondylitis. J Rheumatol 27: 2302–2304.
38. Mielants H. Veys E. Cuvelier C. de Vos M. (1988) Ileocolonoscopy and Spondarthritis. Br J Rheumatol 27: 163–164.
39. Mielants H. Veys E. Goemaere S. Goethals K. Cuvelier C. de Vos M. (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18: 1542–1551.
40. Monnet D. Breban M. Hudry C. Dougados M. Brezin A. (2004) Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 111: 802–809.
41. Munoz-Fernandez S. Hidalgo V. Fernandez-Melon J. Schlincker A. Bonilla G. Ruiz-Sancho D. et al. (2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30: 1277–1279.
42. Nash P. Thaci D. Behrens F. Falk F. Kaltwasser J. (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212: 238–249.
43. O'Neill T. Bresnihan B. (1992) The heart in ankylosing spondylitis. Ann Rheum Dis 51: 705–706.
44. Pato E. Banares A. Jover J. Fernandez- Gutierrez B. Godoy F. Morado C. et al. (2000) Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 27: 2198–2202.
45. Peters M. Symmons D. McCarey D. Dijkmans B. Nicola P. Kvien T. et al. (2010 a) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69: 325–331.
46. Peters M. van der Horst-Bruinsma I. Dijkmans B. Nurmohamed M. (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34: 585–592.
47. Peters M. Visman I. Nielen M. van Dillen N. Verheij R. van der Horst-Bruinsma I. et al. (2010 b) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69: 579–581.
48. Poddubnyy D. Rudwaleit M. Haibel H. Listing J. Marker-Hermann E. Zeidler H. et al. (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 29 March (epub ahead of print).
49. Ribeiro P. Morley K. Shapiro L. Garnett R. Hughes G. Goodwin J. (1984) Left ventricular function in patients with ankylosing spondylitis and Reiter's disease. Eur Heart J 5: 419–422.
50. Rosenbaum J. (2004) Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 50: 3736–3737.
51. Rudwaleit M. Claudepierre P. Wordsworth P. Cortina E. Sieper J. Kron M. et al. (2009 a) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36: 801–808.
52. Rudwaleit M. Landewe R. van der Heijde D. Listing J. Brandt J. Braun J. et al. (2009 b) The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68: 770–776.
53. Rudwaleit M. Rodevand E. Holck P. Vanhoof J. Kron M. Kary S. et al. (2009 c) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68: 696–701.
54. Rudwaleit M. van der Heijde D. Landewe R. Akkoc N. Brandt J. Chou C. et al. (2011) The Assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70: 25–31.
55. Rutgeerts P. Sandborn W. Feagan B. Reinisch W. Olson A. Johanns J. et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476.
56. Sandborn W. Hanauer S. Katz S. Safdi M. Wolf D. Baerg R. et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088–1094.
57. Sandborn W. Hanauer S. Rutgeerts P. Fedorak R. Lukas M. Macintosh D. et al. (2007 a) Adalimumab for maintenance treatment of Crohn's disease: results of the classic II trial. Gut 56: 1232–1239.
58. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Colombel J. Panaccione R. et al. (2007 b) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146: 829–838.
59. Sandborn W. Stenson W. Brynskov J. Lorenz R. Steidle G. Robbins J. et al. (2006) Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 4: 203–211.
60. Sieper J. Koenig A. Baumgartner S. Wishneski C. Foehl J. Vlahos B. et al. (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69: 226–229.
61. Song I. Appel H. Haibel H. Loddenkemper C. Braun J. Sieper J. et al. (2008) New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 35: 532–536.
62. Song I. Heldmann F. Rudwaleit M. Haibel H. Weiss A. Braun J. et al. (2011 a) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70: 1108–1110.
63. Song I. Heldmann F. Rudwaleit M. Listing J. Appel H. Braun J. et al. (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62: 1290–1297.
64. Song I. Hermann K. Haibel H. Althoff C. Listing J. Burmester G. et al. (2011 b) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70: 590–596.
65. Tan A. Marzo-Ortega H. O'Connor P. Fraser A. Emery P. McGonagle D. (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63: 1041–1045.
66. Trelle S. Reichenbach S. Wandel S. Hildebrand P. Tschannen B. Villiger P. et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342: c7086.
67. van der Heijde D. Baraf H. Ramos-Remus C. Calin A. Weaver A. Schiff M. et al. (2005 a) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52: 1205–1215.
68. van der Heijde D. Da Silva J. Dougados M. Geher P. van der Horst-Bruinsmas I. Juanola X. et al. (2006 a) Once-weekly 50-mg dosing of etanercept is as effective as twice-weekly dosing in patients with ankylosing spondylitis. Ann Rheum Dis 65: 509–510.
69. van der Heijde D. Dijkmans B. Geusens P. Sieper J. Dewoody K. Williamson P. et al. (2005 b) Efficacy and safety of infliximab in patients with ankylosing spondylitis – results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52: 582–591.
70. van der Heijde D. Kivitz A. Schiff M. Sieper J. Dijkmans B. Braun J. et al. (2006 b) Efficacy and safety of adalimumab in patients with ankylosing spondylitis - results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54: 2136–2146.
71. van der Horst-Bruinsma I. Clegg D. Dijkmans B. (2002) Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 20: S67–S70.
72. van der Horst-Bruinsma I. van Denderen J. Visman I. Suttorp-Schulten M. Dijkmans B. Nurmohamed M. (2010) Decreased recurrence rate of anterior uveitis in ankylosing spondylitis treated with adalimumab – an interim analysis. Clin Exp Rheumatol 28: 630–630.
73. van der Linden S. Valkenburg H. Cats A. (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York Criteria. Arthritis Rheum 27: 361–368.
74. van der Weijden M. Claushuis T. Nazari T. Lems W. Dijkmans B. van der Horst-Bruinsma I. (2012 a) High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 16 June (epub ahead of print).
75. van der Weijden M. van der Horst-Bruinsma I. van Denderen J. Dijkmans B. Heymans M. Lems W. (2012 b) High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 23: 1683–1690.
76. Vastesaeger N. van der Heijde D. Inman R. Wang Y. Deodhar A. Hsu B. et al. (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70: 973–981.
77. Wakefield D. Chang J. Amjadi S. Maconochie Z. Abu El-Asrar A. Mccluskey P. (2011) What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm 19: 139–144.
78. Wanders A. Heijde D. Landewe R. Behier J. Calin A. Olivieri I. et al. (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52: 1756–1765.
79. Zochling J. van der Heijde D. Dougados M. Braun J. (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65: 423–432.